TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Urocortin, human |
| CAS NO. | / |
| Appearance | Lyophilized white to off-white amorphous powder |
| Molecular Formula | C204H337N63O64 |
| Molecular Weight | 4696.3/mol |
| Purity (RP-HPLC) | ≥98% |
| Solubility | Soluble in deionized water, phosphate-buffered saline and dilute acetic acid |
| Endotoxin | ≤1.0 EU/mg |
| Biological Activity | Exerts biological effects at nanomolar concentrations in human primary cell systems and preclinical models |
| Storage Conditions | Lyophilized powder: Long-term storage at -20°C to -80°C. |
| Stock Location | Stock in USA |
| MOQ | 1g |
Urocortin exerts its effects by binding to and activating G protein-coupled corticotropin-releasing factor receptors, CRF1 and CRF2, with a significantly higher affinity for CRF2. Upon receptor activation, it primarily stimulates the Gs signaling pathway, leading to increased adenylate cyclase activity and elevated intracellular cyclic AMP (cAMP) levels.
Human Urocortin is a research peptide and not an approved drug. However, its strong therapeutic potential has been demonstrated in preclinical and early clinical studies. Research indicates significant promise for treating acute decompensated heart failure due to its beneficial hemodynamic effects (increased cardiac output and vasodilation).
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
